Objective: To report a case of melanoma metastatic to the thyroid gland and to review our experience with secondary neoplasms of the thyroid.
INTRODUCTION
Secondary malignancies of the thyroid are rare. Autopsy series report an incidence of secondary thyroid malignancies in 0.5 to 1.8% of unselected autopsies and up to 2.8% of glands studied in cancer patients. [1] [2] [3] Screening ultrasound as well as surveillance CT and 18 FDG-PET for established cancer patients has lead to the increased detection of incidental secondary neoplasms of the thyroid. 9, 10 These lesions frequently harbor malignancy. 4 Treatment of metastatic lesions to the thyroid is not well-established. In this paper, we describe a case report of a rare patient with melanoma metastatic to the thyroid and review our institution's experience with secondary lesions of the thyroid.
CASE REPORT
The patient is a 59-year-old male who in February 2005 was noted to have a suspicious mole on his left occiput. A shave biopsy was consistent with a superficial spreading melanoma, with a Breslow depth of 0.85 mm and Clark's level IV; no ulceration or lymphovascular invasion was found. The patient was noted to have a palpable lymph node in the left occipital region; an FNA was consistent with metastatic melanoma.
Metastatic work-up with a brain MRI and an abdominopelvic CT scan were negative. A chest CT showed a 2.1 cm hypodense nodule consistent with a solitary 18FDG-PET avid region arising from the left lobe of the thyroid gland (Fig. 1) . He underwent a wide excision of the scalp melanoma and a modified radical left neck dissection. Pathology revealed negative margins, with residual malignant melanoma and one of ten lymph nodes positive for metastatic melanoma. Systemic induction interferon therapy was initiated and he was referred to an endocrine surgeon for further evaluation of the thyroid nodule.
The patient denied local symptoms, history of thyroid disease or radiation exposure, and family history of thyroid cancer. On physical exam, he was noted to have a firm and mobile nodule at the lower pole of the left thyroid lobe. A thyroid ultrasound demonstrated a solitary 2.5 × 1.6 × 1.4 cm solid, hypoechoic nodule at the left lower pole of the thyroid (Fig. 2 ) and no cervical adenopathy was noted. A fine needle aspiration (FNA) was performed confirming metastatic melanoma consistent with the known scalp primary. He underwent a left hemi-thyroidectomy and left central lymph node dissection. At exploration, there was a focal 2.5 cm nodule at the left lower pole that was readily mobilized from the surrounding tissues. The final pathology revealed metastatic melanoma within a follicular adenoma with Hürthle cell features and two negative perithyroidal lymph nodes (Figs 3A to F).
He initially did well following his thyroidectomy, but on routine follow-up was noted to have diffuse metastases including liver metastases on CT and numerous osteolytic bone lesions on bone scan. Maintenance interferon therapy was not tolerated and the disease progressed. Palliative 
INSTITUTIONAL REVIEW
All patients with pathologic confirmation of metastatic tumors of the thyroid undergoing thyroidectomy at the Massachusetts General Hospital were studied with Institutional Review Board compliance (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) .
Patients with direct extension from local tumors were excluded. Patient age, gender, presentation, time from diagnosis of primary tumor, treatment, and outcome are retrospectively reviewed. Fourteen patients had pathologically confirmed secondary tumors metastatic to the thyroid gland: five renal cell carcinomas (RCC), two melanomas, two colorectal adenocarcinomas, two nonsmall cell carcinomas of the lung, one breast adenocarcinoma, one fibrosarcoma, and one adenoid-cystic carcinoma. This cohort included six women and seven men with an average age of 64 (SD ± 12) years. Ten out of the 14 patients presented with local symptoms including seven with compressive symptoms, one with dysphagia, one with hoarseness, and one with dyspnea.
Four incidental thyroid nodules were noted on surveillance imaging for the patient's primary malignancy, two on chest CT for two of the RCC patients, and 18FDG-PET for the others (Fig. 1) . Twelve of the 14 patients underwent FNA of the suspicious nodules. Seven of 12 were accurate in identifying the specific primary. Of the other five, one patient underwent three nondiagnostic FNAs prior to surgical confirmation of metastasis, two were falsenegatives, and two were suspicious for malignancy. Seven patients had isolated metastases. Two of the four RCC patients with follow-up are alive with no evidence of disease, and the others lived greater than four years following the diagnosis of thyroid metastasis. Patient demographics, tumor type, presentation, and treatment are illustrated in Table 1 .
DISCUSSION
Secondary malignancies account for 1.4 to 7.5% of all thyroid malignancies and up to 24% of autopsy specimens. RCC is the most common primary followed by lung, breast, and melanoma. 5 Wychulis et al who reported 14 cases of biopsy proven secondary malignancy of the thyroid at the Mayo Clinic from 1907 to 1962. 6 They found a similar distribution of primary tumors including eight RCC, four breast adenocarcinomas, one rectal adenocarcinoma, and one transitional cell carcinoma. A follow-up series reported 43 cases over a ten-year period. Consistent with other reports, the cancer with the highest frequency of thyroid metastases was RCC. In 6/43, the thyroid was the initial site of metastasis. In their series, the mean survival of patients who were treated with thyroidectomy (23/43) was 
CONCLUSION
FNA remains a valuable tool for the diagnosis of secondary malignancies of the thyroid. 5 RCC was the most common primary malignancy and these patients appear to portend the best prognosis. Palliation from locally compressive symptoms is a reasonable indication for surgery and can be performed with low morbidity. Our series and others have shown examples of long-term survival in patients undergoing resection of isolated metastases. 5, 7, 8, 11 
